China Releases List To Encourage Competition
China's National Health Commission issues list of 34 generic drugs that have 'insufficient' competition, seeking public comments.
You may also be interested in...
Patent-linkage and data exclusivity changes have not been implemented in a major overhaul of medicines law in China. But they could still come through patent law updates.
More Indian companies are headed to China, with Cipla the latest to seal a joint venture there, though the firm has previous links with the country. Respiratory products will lead Cipla’s line-up in China, a market seen as a crucial cog in the firm’s future road map.
Alembic has firmed up a joint venture to tap into emerging opportunities in China amid evolving regulations there, and believes the market holds significant promise despite rising price pressures.